Hashim Talib Hashim, Ahmed Qasim Mohammed Alhatemi, Sania Riaz, Mohammedbaqer Ali Al-Ghuraibawi, Arwa S. Alabide, Humza Saeed, Fatimah Abdullah Sulaiman, Mustafa Ali Abd Alhussain, Maythum Ali Shallan, Ahmed Dheyaa Al-Obaidi, Omar Saab, Hasan Al-Obaidi, Ali Talib Hashim, Nooraldin Merza
{"title":"揭开 Resmetirom 的神秘面纱：非酒精性脂肪性肝炎治疗对肝功能和安全性影响的系统回顾和荟萃分析。","authors":"Hashim Talib Hashim, Ahmed Qasim Mohammed Alhatemi, Sania Riaz, Mohammedbaqer Ali Al-Ghuraibawi, Arwa S. Alabide, Humza Saeed, Fatimah Abdullah Sulaiman, Mustafa Ali Abd Alhussain, Maythum Ali Shallan, Ahmed Dheyaa Al-Obaidi, Omar Saab, Hasan Al-Obaidi, Ali Talib Hashim, Nooraldin Merza","doi":"10.1002/jgh3.70025","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aim</h3>\n \n <p>The role of Resmetirom in non-alcoholic steatohepatitis (NASH) represents a promising therapeutic approach in addressing the growing global burden of liver disease. With NASH emerging as a leading cause of liver-related morbidity and mortality worldwide, there is an urgent need for effective treatments. Resmetirom, a selective thyroid hormone receptor-β agonist, offers potential benefits in improving liver histology and metabolic parameters in patients with NASH. This review examines the current evidence surrounding Resmetirom's role in NASH management.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic review and meta-analysis was done by searching in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess) (OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tool was used for assessing risk of bias in randomized controlled trials (RCTs). In the analysis, we used RevMan Cochrane software.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study showed that patients who were treated with Resmetirom had significantly lower low-density lipoprotein-cholesterol (LDL-C) levels (mean difference [MD] −10.45; 95% confidence interval [CI] −15.86 to −5.83; <i>P</i> < 0.001) and alanine aminotransferase (ALT) levels (MD −7.18; 95% CI −12.67 to −1.68; <i>P</i> = 0.01) as compared with those in the placebo group. The risk of adverse events including diarrhea [risk ratio (RR) 1.81; 95% CI 1.40 to 2.35; <i>P</i> < 0.001] and nausea (RR 1.72; 95% CI 1.31 to 2.27; <i>P</i> < 0.001) was significantly increased for the Resmetirom group as compared with the placebo group.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Resmetirom presents a promising therapeutic option for NASH, offering potential benefits in reducing liver fat content and improving histological outcomes. The encouraging results from clinical trials suggest that Resmetirom may address an unmet need in NASH management, providing hope for patients with this progressive liver disease. Further research and long-term studies are warranted to validate its efficacy and safety profile in larger patient populations.</p>\n </section>\n </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"8 10","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444049/pdf/","citationCount":"0","resultStr":"{\"title\":\"Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment\",\"authors\":\"Hashim Talib Hashim, Ahmed Qasim Mohammed Alhatemi, Sania Riaz, Mohammedbaqer Ali Al-Ghuraibawi, Arwa S. Alabide, Humza Saeed, Fatimah Abdullah Sulaiman, Mustafa Ali Abd Alhussain, Maythum Ali Shallan, Ahmed Dheyaa Al-Obaidi, Omar Saab, Hasan Al-Obaidi, Ali Talib Hashim, Nooraldin Merza\",\"doi\":\"10.1002/jgh3.70025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Aim</h3>\\n \\n <p>The role of Resmetirom in non-alcoholic steatohepatitis (NASH) represents a promising therapeutic approach in addressing the growing global burden of liver disease. With NASH emerging as a leading cause of liver-related morbidity and mortality worldwide, there is an urgent need for effective treatments. Resmetirom, a selective thyroid hormone receptor-β agonist, offers potential benefits in improving liver histology and metabolic parameters in patients with NASH. This review examines the current evidence surrounding Resmetirom's role in NASH management.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A systematic review and meta-analysis was done by searching in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess) (OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tool was used for assessing risk of bias in randomized controlled trials (RCTs). In the analysis, we used RevMan Cochrane software.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The study showed that patients who were treated with Resmetirom had significantly lower low-density lipoprotein-cholesterol (LDL-C) levels (mean difference [MD] −10.45; 95% confidence interval [CI] −15.86 to −5.83; <i>P</i> < 0.001) and alanine aminotransferase (ALT) levels (MD −7.18; 95% CI −12.67 to −1.68; <i>P</i> = 0.01) as compared with those in the placebo group. The risk of adverse events including diarrhea [risk ratio (RR) 1.81; 95% CI 1.40 to 2.35; <i>P</i> < 0.001] and nausea (RR 1.72; 95% CI 1.31 to 2.27; <i>P</i> < 0.001) was significantly increased for the Resmetirom group as compared with the placebo group.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Resmetirom presents a promising therapeutic option for NASH, offering potential benefits in reducing liver fat content and improving histological outcomes. The encouraging results from clinical trials suggest that Resmetirom may address an unmet need in NASH management, providing hope for patients with this progressive liver disease. Further research and long-term studies are warranted to validate its efficacy and safety profile in larger patient populations.</p>\\n </section>\\n </div>\",\"PeriodicalId\":45861,\"journal\":{\"name\":\"JGH Open\",\"volume\":\"8 10\",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444049/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JGH Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的：Resmetirom 在非酒精性脂肪性肝炎（NASH）中的作用代表了一种很有前景的治疗方法，可解决全球日益沉重的肝病负担。随着非酒精性脂肪性肝炎成为全球肝脏相关疾病发病率和死亡率的主要原因，迫切需要有效的治疗方法。Resmetirom是一种选择性甲状腺激素受体-β激动剂，在改善NASH患者的肝脏组织学和代谢参数方面具有潜在的益处。本综述研究了有关雷美替罗在NASH治疗中作用的现有证据：通过在 Cochrane Central Register of Controlled Trials (CENTRAL)、PubMed、MEDLINE (包括 MEDLINE InProcess) (OvidSP)、Web of Science、Embase (OvidSP) 和 Scopus 数据库中检索，进行了系统综述和荟萃分析。ROB2 Cochrane 工具用于评估随机对照试验（RCT）的偏倚风险。在分析中，我们使用了RevMan Cochrane软件：研究显示，与安慰剂组相比，接受雷美替罗治疗的患者低密度脂蛋白胆固醇（LDL-C）水平明显降低（平均差[MD] -10.45；95%置信区间[CI] -15.86至-5.83；P P = 0.01）。包括腹泻在内的不良事件风险[风险比（RR）为1.81；95% CI为1.40至2.35；P P 结论：Resmetirom 是治疗 NASH 的一种很有前景的选择，在降低肝脏脂肪含量和改善组织学结果方面具有潜在的益处。临床试验取得的令人鼓舞的结果表明，Resmetirom 可以满足 NASH 治疗中尚未满足的需求，为这种进展性肝病患者带来希望。为了在更大的患者群体中验证其疗效和安全性，有必要开展进一步的研究和长期研究。
Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment
Background and Aim
The role of Resmetirom in non-alcoholic steatohepatitis (NASH) represents a promising therapeutic approach in addressing the growing global burden of liver disease. With NASH emerging as a leading cause of liver-related morbidity and mortality worldwide, there is an urgent need for effective treatments. Resmetirom, a selective thyroid hormone receptor-β agonist, offers potential benefits in improving liver histology and metabolic parameters in patients with NASH. This review examines the current evidence surrounding Resmetirom's role in NASH management.
Methods
A systematic review and meta-analysis was done by searching in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess) (OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tool was used for assessing risk of bias in randomized controlled trials (RCTs). In the analysis, we used RevMan Cochrane software.
Results
The study showed that patients who were treated with Resmetirom had significantly lower low-density lipoprotein-cholesterol (LDL-C) levels (mean difference [MD] −10.45; 95% confidence interval [CI] −15.86 to −5.83; P < 0.001) and alanine aminotransferase (ALT) levels (MD −7.18; 95% CI −12.67 to −1.68; P = 0.01) as compared with those in the placebo group. The risk of adverse events including diarrhea [risk ratio (RR) 1.81; 95% CI 1.40 to 2.35; P < 0.001] and nausea (RR 1.72; 95% CI 1.31 to 2.27; P < 0.001) was significantly increased for the Resmetirom group as compared with the placebo group.
Conclusion
Resmetirom presents a promising therapeutic option for NASH, offering potential benefits in reducing liver fat content and improving histological outcomes. The encouraging results from clinical trials suggest that Resmetirom may address an unmet need in NASH management, providing hope for patients with this progressive liver disease. Further research and long-term studies are warranted to validate its efficacy and safety profile in larger patient populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
